The antibody technology platform is based on expression cloning of monoclonal antibodies from human B-cells and enables the identification of anti-infective antibodies to prevent and treat infectious diseases.

Intercell will focus its future antibody discovery activities on medically and commercially attractive AIP® derived disease targets including Group B Streptococcus and bacteria involved in hospital-acquired infections.

What are Anti-Infective Monoclonal Antibodies?

The idea of specifically using antibodies as therapeutics against various diseases was conceived more than 100 years ago. Antibodies are natural weapons which can be used to remove foreign substances from the human body. It is this ability which researchers seek to exploit when developing antibody drugs.

Monoclonal antibodies are modelled on natural antibodies. They are specialized, targeted antibodies which are produced synthetically by means of biotechnological processes. What is special about these is that they are able to activate the body’s natural defence mechanisms against the disease.

The advantage of humanized monoclonal antibodies over conventional medicines is that they act on a disease process in a targeted and selective manner and, as a rule, are very well tolerated.

Anti-infective antibodies are used to combat infectious diseases.

Intercell acquired the Antibody Technology Platform from Cytos in 2010 .